StreetInsider.com News Articles

Form 6-K SINOVAC BIOTECH LTD For: Aug 17

Mon, 17 Aug 2026 08:12:00 -0400

si-local-file:///var/storage/secattach/20260817/26935201.html

Form 6-K SINOVAC BIOTECH LTD For: Aug 17

Mon, 17 Aug 2026 08:12:00 -0400

si-local-file:///var/storage/secattach/20260817/26935201.html

SINOVAC Reports Unaudited First Half of 2026 Financial Results

Mon, 17 Aug 2026 08:00:00 -0400

BEIJING--(BUSINESS WIRE)-- Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it filed its unaudited financial results for the six months ended June 30, 2026 with the U.S. Securities and Exchange Commission. An electronic copy of the financial results can be accessed at the Company’s website at www.sinovac.com and at the SEC’s website www.sec.gov.

First Half of 2026 Financial Summary

Sales for the six months ended June 30, 2026 were $147.1 million, compared to $130.3 million in the prior year

SINOVAC Reports Unaudited First Half of 2026 Financial Results

Mon, 17 Aug 2026 08:00:00 -0400

First Half of 2026 Financial Summary

Sales for the six months ended June 30, 2026 were $147.1 million, compared to $130.3 million in the prior year

SINOVAC Reports Unaudited First Half of 2026 Financial Results

Mon, 17 Aug 2026 08:00:00 -0400

First Half of 2026 Financial Summary

Sales for the six months ended June 30, 2026 were $147.1 million, compared to $130.3 million in the prior year

SINOVAC Reports Unaudited First Half of 2026 Financial Results

Mon, 17 Aug 2026 08:00:00 -0400

First Half of 2026 Financial Summary

Sales for the six months ended June 30, 2026 were $147.1 million, compared to $130.3 million in the prior year

SINOVAC Reports Unaudited First Half of 2026 Financial Results

Mon, 17 Aug 2026 08:00:00 -0400

First Half of 2026 Financial Summary

Sales for the six months ended June 30, 2026 were $147.1 million, compared to $130.3 million in the prior year

SINOVAC Reports Unaudited First Half of 2026 Financial Results

Mon, 17 Aug 2026 08:00:00 -0400

First Half of 2026 Financial Summary

Sales for the six months ended June 30, 2026 were $147.1 million, compared to $130.3 million in the prior year

SINOVAC Reports Unaudited First Half of 2026 Financial Results

Mon, 17 Aug 2026 08:00:00 -0400

First Half of 2026 Financial Summary

Sales for the six months ended June 30, 2026 were $147.1 million, compared to $130.3 million in the prior year

SINOVAC Reports Unaudited First Half of 2026 Financial Results

Mon, 17 Aug 2026 08:00:00 -0400

First Half of 2026 Financial Summary

Sales for the six months ended June 30, 2026 were $147.1 million, compared to $130.3 million in the prior year

Form 6-K SINOVAC BIOTECH LTD For: Jul 15

Wed, 15 Jul 2026 06:10:00 -0400

si-local-file:///var/storage/secattach/20260715/26770416.html

Form 6-K SINOVAC BIOTECH LTD For: Jul 15

Wed, 15 Jul 2026 06:10:00 -0400

si-local-file:///var/storage/secattach/20260715/26770416.html

SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend